On-Demand CME Videos
Managing Atopic Dermatitis from Head-to-Toe with JAK Inhibitors: Online CME Activity
This activity was recorded at the 2023 Winter Clinical Dermatology Conference-Hawaii and Winter Clinical Dermatology Conference-Miami. This is a compilation of the 'best of' both sessions.
Seminar-in-Depth: Managing Atopic Dermatitis from Head-to-Toe with JAK Inhibitors
This activity is supported by an educational grant from Incyte.
In order to ensure educational material is relevant, educational materials will expire after a certain time period. This course will be available for the following dates:
April 28, 2023
April 28, 2024
At the completion of this activity, participants should be better able to:
Describe the clinical trial data on JAK inhibitors for the management of atopic dermatitis (AD)
Identify patients who would benefit from the management of AD with JAK inhibitors
Construct a treatment plan to manage patients with AD on JAK inhibitors
James Del Rosso, DO
Adjunct Clinical Professor, Dermatology
Touro University Nevada
Brad Glick, DO, MPH
Program Director, Dermatology Residency
Larkin Community Hospital Palm Springs Campus
Linda Stein Gold, MD
Director Clinical Research
Henry Ford Health System
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Nevada and CMEsquared. The University of Nevada is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The University of Nevada designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures & Disclaimers
CONFLICTS OF INTEREST/DISCLOSURES
In accordance with the ACCME Standards for Commercial Support, balance, independence, objectivity, and scientific rigor are ensured in all CME activities. This requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with any ineligible companies. In addition, the content of this material has been approved by an independent peer reviewer.
Disclosures are as follows:
Grant/Research Support: Aclaris, Amgen, Anaptys Bio, Arcutis, Athenex, Bausch (Ortho), Biorasi, Botanix, Brickell, Cara Therapeutics, Cassiopea, Dermavant, EPI Health, Galderma, Genentech, Incyte, Janssen, LEO, Lilly, Novan, Pfizer, Ralexar, Sanofi Genzyme Regeneron, Sol-Gel, SUN, Vyne
Consultant: Abbvie, Aclaris, Almirall, Amgen, Arcuits, Bausch (Ortho), Biofrontera, Biopharmx, Blue Creek, BMS, Cassiopea, Dermata, Dermavant, Encore, EPI Health, Evoummune, Ferndale, Galderma, Incyte, Jem Health, LEO, La Roche Posay, Lilly, MC2, Novan, Pfizer, Sanofi Genzyme Regeneron, Sente, Sol-Gel, Sonoma, SUN, UCB, Verrica, Vyne
Speakers’ Bureau or Honoraria: Abbvie, Aclaris, Almiral, Amgen, Bausch (Ortho), Biofrontera, Encore, EPI Health Ferndale, Galderma, Genentech, Jem Health, LEO, Lilly, Pfizer, Sanofi Genzyme Regeneron, SUN, UCB, Verrica, Vyne
Ownership interst: Top MD stock
Grant/Research Support: Arcutis, BMS, Incyte, Dermavant, Galderma, Lilly, AbbVie
Consultant: Arcutis, BMS, Incyte, Dermavant, Galderma, Lilly, AbbVie
Speakers’ Bureau or Honoraria: Leo, AbbVie, Almirall, Galderma, Pfizer, Sanofi, Regeneron
The planners have disclosed that they have no relevant financial relationships with any Ineligible Company in the past 24 months.
The University of Nevada discloses that all relevant conflicts have been satisfactorily mitigated.